Testing the drug mix Opdualag for high-grade glioma and DIPG with a DNA repair problem
Original title: Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle-stage test in people, not proven care yet.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests how well people with a certain kind of brain tumor handle a mix of two drugs.
Who this trial is for. This trial is for people with high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary, including DIPG, whose tumor has trouble fixing mistakes in its DNA. It tests Opdualag, which combines two drugs called relatlimab and nivolumab.
Where it stands. The team wants to learn how well patients handle Opdualag. They also want to see if giving it works in practice. This trial has not reported any results yet.
What this means, and what it doesn't
What it could mean: If your tumor has this DNA repair problem, this trial may be worth asking about. Your care team can help you see if it might fit. The trial team decides who can join.
What it doesn't mean: A trial is a test, not a proven treatment. We do not yet know if Opdualag helps these tumors. Being in a trial does not promise it will help you. This is not a cure.
Source: ClinicalTrials.gov, September 9, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.